JP2016540517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540517A5 JP2016540517A5 JP2016540970A JP2016540970A JP2016540517A5 JP 2016540517 A5 JP2016540517 A5 JP 2016540517A5 JP 2016540970 A JP2016540970 A JP 2016540970A JP 2016540970 A JP2016540970 A JP 2016540970A JP 2016540517 A5 JP2016540517 A5 JP 2016540517A5
- Authority
- JP
- Japan
- Prior art keywords
- regions
- uracil
- stranded
- double
- reversible inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- 108091034117 Oligonucleotide Proteins 0.000 claims 9
- 108020004414 DNA Proteins 0.000 claims 8
- 239000013037 reversible inhibitor Substances 0.000 claims 8
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical group NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 8
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims 8
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 claims 8
- 102000053602 DNA Human genes 0.000 claims 6
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 6
- 229920000768 polyamine Polymers 0.000 claims 6
- 229940035893 uracil Drugs 0.000 claims 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims 5
- 239000011541 reaction mixture Substances 0.000 claims 5
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 claims 4
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 229940063673 spermidine Drugs 0.000 claims 4
- 229940063675 spermine Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 230000003321 amplification Effects 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000009897 systematic effect Effects 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919520P | 2013-12-20 | 2013-12-20 | |
| US61/919,520 | 2013-12-20 | ||
| PCT/EP2014/078350 WO2015091720A1 (en) | 2013-12-20 | 2014-12-18 | An improved oligonucleotide inhibitor of dna polymerases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016540517A JP2016540517A (ja) | 2016-12-28 |
| JP2016540517A5 true JP2016540517A5 (enExample) | 2018-02-01 |
| JP6608826B2 JP6608826B2 (ja) | 2019-11-20 |
Family
ID=52358740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540970A Active JP6608826B2 (ja) | 2013-12-20 | 2014-12-18 | Ｄｎａポリメラーゼの改良されたオリゴヌクレオチド阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10036061B2 (enExample) |
| EP (1) | EP3083961B1 (enExample) |
| JP (1) | JP6608826B2 (enExample) |
| CN (1) | CN105874069B (enExample) |
| CA (1) | CA2930926C (enExample) |
| WO (1) | WO2015091720A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6490576B2 (ja) * | 2012-04-12 | 2019-03-27 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | 重合反応のための合成核酸 |
| EP3464596B1 (en) * | 2016-06-07 | 2025-07-30 | Cepheid | Thermostable polymerase inhibitor compositions and methods |
| US10669580B2 (en) * | 2016-08-26 | 2020-06-02 | Roche Sequencing Solutions, Inc. | Tagged nucleotides useful for nanopore detection |
| US10724017B1 (en) * | 2017-12-06 | 2020-07-28 | Cepheid | Inhibition of DNA polymerases by uracil-DNA glycosylase-cleavable oligonucleotide ligands |
| US10689629B1 (en) | 2017-12-06 | 2020-06-23 | Cepheid | Inhibition of nucleic acid polymerases by endonuclease V-cleavable circular oligonucleotide ligands |
| US10724083B1 (en) | 2017-12-06 | 2020-07-28 | Cepheid | Inhibition of nucleic acid polymerases by endonuclease V-cleavable oligonucleotide ligands |
| CN112251441B (zh) * | 2020-10-26 | 2021-08-17 | 集美大学 | 一种具有靶向抑制鳗弧菌的核酸适配体h7及其应用 |
| WO2023092128A2 (en) * | 2021-11-22 | 2023-05-25 | Integrated Dna Technologies, Inc. | Aptamers for the reversible inhibition of dna polymerases |
| JP7514460B2 (ja) * | 2022-03-31 | 2024-07-11 | 邦明 長峯 | ポリアミンの検出方法、ポリアミンの検出試薬及びアプタマ |
| WO2026136820A1 (en) * | 2024-12-20 | 2026-06-25 | Cepheid | Dna polymerase inhibitor |
| WO2026164135A1 (ja) * | 2025-01-30 | 2026-08-06 | 国立研究開発法人産業技術総合研究所 | 耐熱性ｄｎａポリメラーゼの活性を阻害するオリゴヌクレオチドアプタマー |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1466018B2 (en) * | 2002-01-08 | 2015-08-12 | Roche Diagnostics GmbH | Use of silica material in an amplification reaction |
| AU2006269282B2 (en) * | 2005-07-07 | 2013-10-24 | Quanta Biosciences, Inc. | Compositions and methods for increasing amplification efficiency |
| US8669061B2 (en) * | 2008-06-26 | 2014-03-11 | Roche Molecular Systems, Inc. | Method for the prevention of carryover contamination in nucleic acid amplification technologies |
| CA2688174C (en) | 2008-12-19 | 2018-08-07 | F. Hoffmann-La Roche Ag | Dry composition of reaction compounds with stabilized polymerase |
-
2014
- 2014-12-05 US US14/562,351 patent/US10036061B2/en active Active
- 2014-12-18 WO PCT/EP2014/078350 patent/WO2015091720A1/en not_active Ceased
- 2014-12-18 CA CA2930926A patent/CA2930926C/en active Active
- 2014-12-18 EP EP14828022.5A patent/EP3083961B1/en active Active
- 2014-12-18 CN CN201480069584.6A patent/CN105874069B/zh active Active
- 2014-12-18 JP JP2016540970A patent/JP6608826B2/ja active Active
-
2018
- 2018-06-19 US US16/012,402 patent/US10683540B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016195614A5 (enExample) | ||
| WO2015081229A3 (en) | Selective amplification of nucleic acid sequences | |
| JP2017537658A5 (enExample) | ||
| CN112020562A (zh) | 基于crispr效应系统的诊断 | |
| NZ723399A (en) | Methods and compositions for dna profiling | |
| JP2010535480A5 (enExample) | ||
| JP2017532044A5 (enExample) | ||
| MX2010004984A (es) | Uso de oligonucleotidos con bases modificadas en hibridacion de acidos nucleicos. | |
| NZ608313A (en) | Direct capture, amplification and sequencing of target dna using immobilized primers | |
| JP2010142229A5 (enExample) | ||
| JP2012514451A5 (enExample) | ||
| SG10201808952WA (en) | Systems and methods for clonal replication and amplification of nucleic acid molecules for genomic and therapeutic applications | |
| JP2016500275A5 (enExample) | ||
| JP2011101652A5 (enExample) | ||
| JP2017508474A5 (enExample) | ||
| RU2015150098A (ru) | Способ амплификации днк на основе внедрения в цепь | |
| RU2015123459A (ru) | Одновременная детекция белка-мишени и нуклеиновых кислот-мишеней в одной клетке | |
| WO2015148218A3 (en) | Isothermal amplification under low salt condition | |
| JP2017530715A5 (enExample) | ||
| GB0712882D0 (en) | Nucleic acid amplification | |
| WO2014143714A3 (en) | Methods for one step nucleic acid amplification of non-eluted samples | |
| JP2017514478A5 (enExample) | ||
| JP2017521086A5 (enExample) | ||
| JP2018068317A5 (enExample) | ||
| JP2013515458A5 (enExample) |